Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation

L. J. Rubin, P. Nicod, L. D. Hillis, B. G. Firth

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients. Nifedipine treatment increased cardiac output (mean ± SD, 3.6 ± 1.7 to 5.3 ± 2.8 L/min, p<0.001) and decreased mean aortic pressure (99 ± 19 to 85 ± 12 mm Hg, p<0.001) and total pulmonary and total systemic resistances (1605 ± 787 to 1025 ± 540 dyn · s · cm-5 and 2761 ± 1557 to 1591 ± 823 dyn · s · cm-5, respectively; p<0.005). Heart rate and mean pulmonary arterial pressure did not change significantly. Right ventricular end-diastolic volume decreased 10% (p = 0.01), end-systolic volume decreased 15% (p<0.01), and right ventricular ejection fraction increased 18% (p<0.05) in eight patients. After 4 to 14 months (mean, 7.3 ± 3.8) of treatment with nifedipine, 40 to 129 mg/d, in six patients, cardiac output increased (3.6 ± 2.0 to 5.0 ± 1.8 L/min, p<0.01) and total pulmonary resistance decreased (1572 ± 730 to 987 ± 586 dyn · s · cm-5, p = 0.025), whereas pulmonary arterial pressure remained unchanged (59 ± 23.2 to 55 ± 28.6 mm Hg, p>0.05) compared with baseline values. We conclude that nifedipine therapy may be useful in the chronic management of patients with primary pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalAnnals of Internal Medicine
Volume99
Issue number4
StatePublished - 1983
Externally publishedYes

Fingerprint

Nifedipine
Hemodynamics
Therapeutics
Cardiac Output
Familial Primary Pulmonary Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. / Rubin, L. J.; Nicod, P.; Hillis, L. D.; Firth, B. G.

In: Annals of Internal Medicine, Vol. 99, No. 4, 1983, p. 433-438.

Research output: Contribution to journalArticle

Rubin, L. J. ; Nicod, P. ; Hillis, L. D. ; Firth, B. G. / Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. In: Annals of Internal Medicine. 1983 ; Vol. 99, No. 4. pp. 433-438.
@article{0c8ccd35dd724d19bbe026ac68684820,
title = "Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation",
abstract = "To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients. Nifedipine treatment increased cardiac output (mean ± SD, 3.6 ± 1.7 to 5.3 ± 2.8 L/min, p<0.001) and decreased mean aortic pressure (99 ± 19 to 85 ± 12 mm Hg, p<0.001) and total pulmonary and total systemic resistances (1605 ± 787 to 1025 ± 540 dyn · s · cm-5 and 2761 ± 1557 to 1591 ± 823 dyn · s · cm-5, respectively; p<0.005). Heart rate and mean pulmonary arterial pressure did not change significantly. Right ventricular end-diastolic volume decreased 10{\%} (p = 0.01), end-systolic volume decreased 15{\%} (p<0.01), and right ventricular ejection fraction increased 18{\%} (p<0.05) in eight patients. After 4 to 14 months (mean, 7.3 ± 3.8) of treatment with nifedipine, 40 to 129 mg/d, in six patients, cardiac output increased (3.6 ± 2.0 to 5.0 ± 1.8 L/min, p<0.01) and total pulmonary resistance decreased (1572 ± 730 to 987 ± 586 dyn · s · cm-5, p = 0.025), whereas pulmonary arterial pressure remained unchanged (59 ± 23.2 to 55 ± 28.6 mm Hg, p>0.05) compared with baseline values. We conclude that nifedipine therapy may be useful in the chronic management of patients with primary pulmonary hypertension.",
author = "Rubin, {L. J.} and P. Nicod and Hillis, {L. D.} and Firth, {B. G.}",
year = "1983",
language = "English (US)",
volume = "99",
pages = "433--438",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation

AU - Rubin, L. J.

AU - Nicod, P.

AU - Hillis, L. D.

AU - Firth, B. G.

PY - 1983

Y1 - 1983

N2 - To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients. Nifedipine treatment increased cardiac output (mean ± SD, 3.6 ± 1.7 to 5.3 ± 2.8 L/min, p<0.001) and decreased mean aortic pressure (99 ± 19 to 85 ± 12 mm Hg, p<0.001) and total pulmonary and total systemic resistances (1605 ± 787 to 1025 ± 540 dyn · s · cm-5 and 2761 ± 1557 to 1591 ± 823 dyn · s · cm-5, respectively; p<0.005). Heart rate and mean pulmonary arterial pressure did not change significantly. Right ventricular end-diastolic volume decreased 10% (p = 0.01), end-systolic volume decreased 15% (p<0.01), and right ventricular ejection fraction increased 18% (p<0.05) in eight patients. After 4 to 14 months (mean, 7.3 ± 3.8) of treatment with nifedipine, 40 to 129 mg/d, in six patients, cardiac output increased (3.6 ± 2.0 to 5.0 ± 1.8 L/min, p<0.01) and total pulmonary resistance decreased (1572 ± 730 to 987 ± 586 dyn · s · cm-5, p = 0.025), whereas pulmonary arterial pressure remained unchanged (59 ± 23.2 to 55 ± 28.6 mm Hg, p>0.05) compared with baseline values. We conclude that nifedipine therapy may be useful in the chronic management of patients with primary pulmonary hypertension.

AB - To evaluate the potential value of nifedipine treatment for primary pulmonary hypertension, hemodynamic and scintigraphic measurements were made before and 15 to 30 minutes after nifedipine, 10 to 20 mg, was given sublingually to nine patients. Nifedipine treatment increased cardiac output (mean ± SD, 3.6 ± 1.7 to 5.3 ± 2.8 L/min, p<0.001) and decreased mean aortic pressure (99 ± 19 to 85 ± 12 mm Hg, p<0.001) and total pulmonary and total systemic resistances (1605 ± 787 to 1025 ± 540 dyn · s · cm-5 and 2761 ± 1557 to 1591 ± 823 dyn · s · cm-5, respectively; p<0.005). Heart rate and mean pulmonary arterial pressure did not change significantly. Right ventricular end-diastolic volume decreased 10% (p = 0.01), end-systolic volume decreased 15% (p<0.01), and right ventricular ejection fraction increased 18% (p<0.05) in eight patients. After 4 to 14 months (mean, 7.3 ± 3.8) of treatment with nifedipine, 40 to 129 mg/d, in six patients, cardiac output increased (3.6 ± 2.0 to 5.0 ± 1.8 L/min, p<0.01) and total pulmonary resistance decreased (1572 ± 730 to 987 ± 586 dyn · s · cm-5, p = 0.025), whereas pulmonary arterial pressure remained unchanged (59 ± 23.2 to 55 ± 28.6 mm Hg, p>0.05) compared with baseline values. We conclude that nifedipine therapy may be useful in the chronic management of patients with primary pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0020604487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020604487&partnerID=8YFLogxK

M3 - Article

C2 - 6625374

AN - SCOPUS:0020604487

VL - 99

SP - 433

EP - 438

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -